This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective and Response Variable: To evaluate soy bread developed by The Ohio State University Food Science and Technology Department for efficacy and safety. The appearance of isoflavones will be measured in the urine. Urinary isoflavones will be quantified at baseline after two-week washout and after consumption of soy product. Differences in urinary isoflavones provide information on newly absorbed isoflavones from the soy product. Secondary Objective(s) and Response Variable(s): 1.tab To compare the absorption and metabolism of isoflavones consumed as soy bread with soy beverage powder. Within the crossover design of this study, the variation between the two urine isoflavone measurements may help to determine whether food matrix of soy foods may enhance the bioavailability of soy isoflavones. 2.tab To define and characterize isoflavones and their metabolites in urine after a three week dietary intervention of soy. To examine the consequences of soy consumption on biomarkers of cardiovascular risk factors, cholesterol (total, LDL, and HDL), triglycerides, isoprostanes, lipoproteins (A-I and B), copper induced LDL oxidation, and C-reactive protein.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000034-46
Application #
7374601
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2005-12-01
Project End
2006-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
46
Fiscal Year
2006
Total Cost
$62,640
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Beversdorf, David Q; Carpenter, Allen L; Alexander, Jessica K et al. (2018) Influence of Serotonin Transporter SLC6A4 Genotype on the Effect of Psychosocial Stress on Cognitive Performance: An Exploratory Pilot Study. Cogn Behav Neurol 31:79-85
Tita, Alan T N; Lai, Yinglei; Landon, Mark B et al. (2017) Predictive Characteristics of Elevated 1-Hour Glucose Challenge Test Results for Gestational Diabetes. Am J Perinatol 34:1464-1469
Criado, Kristen K; Sharp, William G; McCracken, Courtney E et al. (2017) Overweight and obese status in children with autism spectrum disorder and disruptive behavior. Autism :1362361316683888
Lee, Kyoung Suk; Lennie, Terry A; Yoon, Ju Young et al. (2017) Living Arrangements Modify the Relationship Between Depressive Symptoms and Self-care in Patients With Heart Failure. J Cardiovasc Nurs 32:171-179
Landon, Mark B; Grobman, William A; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network (2016) What We Have Learned About Trial of Labor After Cesarean Delivery from the Maternal-Fetal Medicine Units Cesarean Registry. Semin Perinatol 40:281-6
Blackwell, Sean C; Landon, Mark B; Mele, Lisa et al. (2016) Relationship Between Excessive Gestational Weight Gain and Neonatal Adiposity in Women With Mild Gestational Diabetes Mellitus. Obstet Gynecol 128:1325-1332
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Salazar, Ashley; Tolivaisa, Susan; Allard, Donna et al. (2016) What we have learned about best practices for recruitment and retention in multicenter pregnancy studies. Semin Perinatol 40:321-7
Harper, Lorie M; Mele, Lisa; Landon, Mark B et al. (2016) Carpenter-Coustan Compared With National Diabetes Data Group Criteria for Diagnosing Gestational Diabetes. Obstet Gynecol 127:893-8
Kaumaya, Pravin T P (2015) A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 11:1368-86

Showing the most recent 10 out of 426 publications